AV
AVCNF.US Avicanna Inc
- Market cap
- USD 9.27M
- P/E
- -
- P/B
- 2.65x
- ROE
- -69.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AVCNF.US undervalued?
Graham numberThe Graham number of Avicanna Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Avicanna Inc fundamental analysis
No fundamental analysis for Avicanna Inc yet.
Avicanna Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific cannabinoid-b…
Full company profileAvicanna Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Avicanna Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 26.7K | 118K | 168K | 1.57M | 3.27M | 4.05M | 16.8M | 25.5M | 25.5M | 24.6M |
| Gross Profit | - | 26.7K | -4.31K | 92.1K | -570K | 2.83M | 1.12M | 6.66M | 12.2M | 13.5M | 14.1M |
| Operating Income | -29.8K | -2.59M | -8.32M | -23.2M | -19.0M | -11.4M | -10.4M | -8.38M | -5.64M | -2.78M | -2.74M |
| EBITDA | - | -2.52M | -8.15M | -22.3M | -33.7M | -15.1M | -12.2M | -7.36M | -3.39M | -1.96M | -2.44M |
| Net Income | -29.8K | -2.60M | -7.10M | -21.1M | -32.9M | -16.8M | -14.7M | -8.74M | -3.99M | -2.84M | -3.20M |
| EPS | - | -0.12 | -0.32 | -0.94 | -0.92 | -0.37 | -0.20 | -0.10 | -0.04 | -0.02 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 93.0K | 2.12M | 28.2M | 45.2M | 30.2M | 22.3M | 17.6M | 22.0M | 19.4M | 21.2M | 24.1M |
| Total Liabilities | 123K | 1.28M | 1.80M | 15.3M | 16.2M | 15.4M | 14.2M | 14.0M | 9.71M | 9.86M | 10.1M |
| Shareholders' Equity | -29.8K | 841K | 26.4M | 29.9M | 13.9M | 6.91M | 3.46M | 7.97M | 2.62M | 2.84M | 4.60M |
| Cash & Short-term Investments | 91.4K | 1.18M | 69.3K | 442K | 1.27M | 31.0K | 1.19M | 477K | 448K | 281K | 200K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -223K | -2.13M | -4.99M | -17.8M | -14.0M | -11.7M | -7.44M | -1.40M | -2.55M | -1.18M | -3.90M |
| Capital Expenditure | 512K | 512K | 3.87M | 7.92M | 1.62M | 769K | 66.8K | 558K | 403K | 256K | 353K |
| Free Cash Flow | - | -2.65M | -8.91M | -26.9M | -15.4M | -12.5M | -7.50M | -1.96M | -2.95M | -1.44M | -4.26M |
| Ratios | |||||||||||
| ROE | - | -309.1% | -26.9% | -70.5% | -236.2% | -242.8% | -426.0% | -109.7% | -152.4% | -100.0% | -69.6% |
| ROA | -32.1% | -122.8% | -25.2% | -46.7% | -109.0% | -75.2% | -83.6% | -39.8% | -20.6% | -13.4% | -13.3% |
| Net Profit Margin | - | -9,750.5% | -6,017.6% | -12,524.1% | -2,093.0% | -513.2% | -364.0% | -52.1% | -15.7% | -11.2% | -13.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Avicanna Inc dividends
Avicanna Inc has not paid dividends in the last 9 fiscal years.
Who owns Avicanna Inc
- Insiders 21.29%
- Institutions 0.00%
- Public & others 78.71%
- Shares outstanding 134M
- Free float 118M
Avicanna Inc company profile
- Company name
- Avicanna Inc
- Ticker
- AVCNF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 112
- Fiscal year end
- December
- Address
- 480 University Avenue, Toronto, ON, Canada, M5G 1V2
- Phone
- 647 243 5283
- Website
- avicanna.com
About Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific cannabinoid-based candidates to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, as well as Trunerox, an indication-specific drug treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, as well as provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens; and collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
Avicanna Inc management
6- Mr. Aras Azadian B.Econ, MbaCo-Founder, CEO & Director
- Mr. Nick Hilborn C.A., CPAChief Financial Officer
- Mr. Stephen KimChief Legal Officer, General Counsel & Corporate Secretary
- Ms. Ivana MaricExecutive Vice President of Marketing
- Dr. Karolina UrbanExecutive Vice President of Scientific & Medical Affairs
- Dr. Carlos Enrique Maldonado MueteSVP of Clinical Development